Table 1.
Demographic Information of the participants in the PK substudy. SD: standard deviation
| Treatment Group | ||||
|---|---|---|---|---|
| Characteristic | Total (N=48) | LDMTX (N=20) | Placebo (N=28) | |
| Sex | M | 44 (92%) | 17 (85%) | 27 (96%) |
| F | 4 (8%) | 3 (15%) | 1 (4%) | |
| Race | Black or African American | 22 (46%) | 9 (45%) | 13 (46%) |
| White | 24 (50%) | 10 (50%) | 14 (50%) | |
| More than One Race | 1 (2%) | 0 (0%) | 1 (4%) | |
| Unknown | 1 (2%) | 1 (5%) | 0 (0%) | |
| Race/Ethnicity | White Non-Hispanic | 23 (48%) | 9 (45%) | 14 (50%) |
| Black Non-Hispanic | 22 (46%) | 9 (45%) | 13 (46%) | |
| Hispanic (Regardless of Race) | 2 (4%) | 2 (10%) | 0 (0%) | |
| More than one race | 1 (2%) | 0 (0%) | 1 (4%) | |
| Age (years) | Median (Q1-Q3) | 54 (49–59) | 56 (52–61) | 52 (49–57) |
| BMI (kg/m2) | # missing | 2 | 0 | 2 |
| Median (Q1-Q3) | 27.5 (24.3–31.1) | 29.1 (24.5–31.2) | 27.4 (24.1–29.8) | |
| Calculated Creatinine Clearance (mL/min) | Median (Q1-Q3) | 98 (84–115) | 110 (86–116) | 96 (81–110) |
| Entry CD4+ Cell Count (cells/mm3) | Median (Q1-Q3) | 731 (625–946) | 687 (539–968) | 756 (649–918) |
| Does the ARV regimen include a concomitant NNRTI | Yes | 24 (50%) | 12 (60%) | 12 (43%) |
| Does the ARV regimen include a concomitant PI | Yes | 17 (35%) | 5 (25%) | 12 (43%) |
| Does the ARV regimen include a concomitant II | Yes | 10 (21%) | 3 (15%) | 7 (25%) |